Lifeist Wellness Expands Mikra's Mind-First Product Portfolio with Three New Performance-Focused Formulations
Mikra partners with leading nutritional supplement brand Designs for Health to introduce new product formulations
TORONTO, July 21, 2025 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. ('Lifeist' or the 'Company') (TSX.V: LFST; OTCQB: LFSWF; FRANKFURT: M5B0), a health-tech wellness company curating and building innovation at the forefront of consumer health, announces the availability of three new Mikra performance-focused daily essentials on
wearemikra.com
. The new products — Magnesium Bis-Glycinate, Coenzymated B Complex, and Omega-3 with EPA & DHA — are foundational daily formulas designed to support core systems that contribute to cognitive performance and mental resilience. Each product is manufactured in partnership with
Designs for Health
, a leading provider of premium-grade, practitioner-trusted supplements known for their precision and purity.
'Offering a complete system of mind-first tools is key to our fundamental shift toward mental performance as the essential foundation of high performance,' said Andrea Judge, CEO of Lifeist Wellness. 'Mikra's Mind-First Movement is about pairing clinical precision with real-world performance. This approach prioritizes focus, cognitive endurance, and complete recovery as primary drivers of peak performance for athletic and for everyday life.'
'We are delighted to partner with Designs for Health, which has decades of formulation expertise and rigorous quality standards,' Judge added. 'This collaboration with Designs for Health has made it possible to bring premium, research-based cognitive support into everyday formulations that match the integrity of our more targeted cognitive solutions.'
The new Mikra formulations support key body systems that play vital roles in helping to unlock higher cognitive performance:
The new products complement Mikra's mind-first supplements each designed to support the connection between mental and physical performance: CLARITY for preparing the mind for the demands ahead, HYDRATE to fuel focus during performance, and CALM to support recovery and nervous system repair afterward. Lifeist plans to unveil a reformulation of its flagship CellF later this summer.
About Designs for Health
Family-owned Designs for Health, Inc. offers high-quality nutritional supplements and functional foods to health care professionals and their patients. Guided by its founding philosophy of 'Science-First™,' the company holds an unwavering commitment to creating research-driven formulations with meaningful quantities of functional ingredients that maximize the potential for successful health outcomes. For over 35 years, Designs for Health has been many health-care professionals' trusted source for not only product innovation but also leadership in clinical education and practice development solutions.
https://www.designsforhealth.com/our-story
About Mikra
Mikra is a performance-focused supplement brand built around a simple idea: the mind leads, and the body follows. Through targeted, science-backed formulations, Mikra is creating a new standard for what it means to support total human performance — starting with cognitive and emotional resilience.
About Lifeist Wellness Inc.
Lifeist is a health-tech wellness company that believes in building performance from within. Through its innovative portfolio of consumer brands — including Mikra — Lifeist is creating a new standard in mental and physical optimization. Learn more at:
www.lifeist.com
|
www.wearemikra.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.
Source: Lifeist Wellness Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today
Key Points Mind Medicine stock is a speculative play on future potential for psychedelics as therapeutic treatments. The stock has underperformed the S&P 500 over the last five years, but it has still delivered positive returns for investors. Mind Medicine is a risky investment, but it's possible the stock could deliver big wins for patient shareholders. 10 stocks we like better than Mind Medicine (MindMed) › Mind Medicine (NASDAQ: MNMD) is a clinical stage biotech company that's aiming to bring psychedelics and other compounds to market as forms of treatments for conditions including generalized anxiety disorder (GAD), major depressive disorder (MDD), and autism spectrum disorder (ASD). The business is still in a pre-revenue state and has a highly uncertain forward performance trajectory, but it's recently garnered an uptick in interest from investors thanks to encouraging clinical trial developments and indications that political and regulatory developments could give the company an easier path to commercialization. Owing in large part to its highly speculative outlook, Mind Medicine stock has seen periods of huge volatility over the last five years. Despite jumping roughly 35% over the last year of trading, the company's share price is actually down roughly 86% from its valuation high in the period. However, Mind Medicine still delivered substantial returns over the last five years. While the stock underperformed the S&P 500 index's total return of roughly 91% over the stretch, it still posted an 87% return over the 12 months ended Aug. 8. If you had invested $1,000 in the stock five years ago and held on to your shares, the position would now be worth roughly $1,875. Can Mind Medicine beat the market over the next five years? Mind Medicine stock is a very risky investment, but it does have avenues to significantly outperform the S&P 500 index over the next five years. The lead treatment in Mind Medicine's pipeline is a modified form of Lysergide D-tartrate, a form of LSD. While the idea of using psychedelics to treat anxiety and depressive disorders may seem unconventional, there is research that points to meaningful efficacy -- and Mind Medicine's early clinical results have supported continued research and trials. The company is set to release Phase III trial results for the treatment next year, and positive data could trigger the early stages of a strong run-up for the stock. Mind Medicine stock comes with a high risk profile, but shares could surge if the biotech specialist successfully brings a treatment to market. Should you buy stock in Mind Medicine (MindMed) right now? Before you buy stock in Mind Medicine (MindMed), consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Mind Medicine (MindMed) wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool Sign in to access your portfolio
Newsweek
5 days ago
- Newsweek
Alzheimer's: Scientists Reveal Diet That May Stave Off Disease
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. While we know some foods can offer medicinal benefits, it appears one diet in particular can help to reduce the risk of dementia and Alzheimer's disease. Sticking to a Mediterranean-style diet may help to slow cognitive decline and ultimately prevent these neurodegenerative diseases, according to scientists at Rush University Medical Center. The researchers measured hippocampal sclerosis (HS)—a severe decline in brain cells and processes in particular areas of the brain linked with dementia and Alzheimer's—in 809 people with available brain autopsies and dietary information. They found those who had been on the 'MIND' diet, which combines elements of the Mediterranean diet with a another called Dietary Approaches to Stop Hypertension (DASH), were less likely to have signs of HS in their brains. This suggests being consistent with the MIND diet may reduce the risk of HS, dementia and Alzheimer's disease, the authors said. Foods in this diet typically include whole grains, nuts, legumes, berries, vegetables (especially leafy greens), olive oil, poultry and fish. Woman looking in fridge thinking about what to eat. Woman looking in fridge thinking about what to eat. shurkin_son/Getty Images "This cohort study of autopsied participants found that MIND diet adherence during follow-up was associated with a lower likelihood of HS, HS with LATE-NC [the most recently identified form of dementia, noted for its similarity to Alzheimer's disease] and hippocampal neuronal loss [damage to neurons in the part of the brain crucial for memory]," the researchers wrote in the study. "The association of diet with dementia was partially mediated by its association with HS. These findings suggest that the MIND diet may reduce adverse brain health outcomes." HS is a common marker of aging characterized by severe neuronal loss and injury in memory-associated regions in the hippocampus. HS is present in 20 percent of individuals with cognitive impairment and is increasingly recognized as an important pathology associated with cognitive impairment and dementia beyond typical Alzheimer's disease pathology, according to the researchers. HS is also associated with LATE-NC, Alzheimer's disease pathology and changes in the size of the hippocampus. Brain health food nutrition concept with fish, vegetables, seeds, pollen grain and herbs on rustic background. Brain health food nutrition concept with fish, vegetables, seeds, pollen grain and herbs on rustic background. marilyna/Getty Images The researchers had previously observed that people with HS showed impairment in hippocampus-dependent cognitive abilities, like memory—while those with both HS and Alzheimer's pathology had lower episodic memory scores than those with Alzheimer's pathology alone. "The fact that HS combined with other pathologies, like LATE-NC or AD, is associated with cognitive impairment or probable dementia suggests that prevention of these pathologies could result in lower risks of dementia. Thus, understanding whether the modifiable risk factors may prevent such pathology that impacts brain health is important for healthy aging," the researchers wrote. While this builds on previous studies suggesting diet is a potentially modifiable risk factor associated with dementia and other age-related cognitive outcomes, including MIND and low-calorie diets, it has been unknown whether MIND is associated with other dementia-related pathologies. This includes HS, LATE-NC (prevalent in individuals with HS), and hippocampal neuronal loss. This study investigated the association using postmortem brain tissue from a community-based sample of older adults and further investigated whether the association of the MIND diet with dementia diagnosis close to the time of death was mediated by HS. "Overall, this study supports that among older adults, adhering to a healthy dietary pattern, such as the MIND diet, is associated with reduced likelihood of hippocampal degeneration of aging, as indicated by HS, HS with LATE-NC and hippocampal neuronal loss," the researchers explained. "Our findings also support that the association of the MIND diet with hippocampal health may partially explain the association of a healthy diet with reduced dementia risk. "Further studies should investigate potential neurobiological mechanisms explaining these links, including neuroinflammation and brain oxidative stress, proposed mechanisms for the association of diet with dementia." Do you have a health story to share with Newsweek? Do you have a question about Alzheimer's? Let us know via health@ Reference Agarwal, P., Agrawal, S., Wagner, M., Cherian, L. J., Aggarwal, N. T., James, B. D., Holland, T. M., Bennett, D. A., Barnes, L. L., Leurgans, S. E., & Schneider, J. A. (2025). MIND diet and hippocampal sclerosis among community-based older adults. JAMA Network Open, 8(8). Wilson, R. S., Yang, J., Yu, L., Leurgans, S. E., Capuano, A. W., Schneider, J. A., Bennett, D. A., & Boyle, P. A. (2019). Postmortem neurodegenerative markers and trajectories of decline in cognitive systems. Neurology, 92(8), e831–e840.
Yahoo
5 days ago
- Yahoo
Izotropic Launches Podcast Episode #1: Beyond the Mammogram: Rethinking the Future of Breast Imaging
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ('Izotropic', or the 'Company'), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of its new podcast series. The first episode Beyond the Mammogram: Rethinking the Future of Breast Imaging is now available in English, Arabic, Chinese, French, German, Italian and Spanish. The podcast marks a new initiative in the Company's ongoing mission to inform and engage broader global audiences about innovations in breast imaging. Through accessible and engaging conversations, the series will explore the evolving landscape of breast cancer detection, highlighting clinical challenges, market dynamics, and the technologies poised to reshape the industry and patient care. In the premiere episode, listeners will hear a compelling discussion about the limitations of current imaging tools, including mammography, digital breast tomosynthesis, ultrasound, and MRI, particularly in screening women with dense breast tissue, who represent approximately 50% of the population. With breast cancer projected to affect over 315,000 women in the U.S. in 2025, the episode highlights the urgent need for imaging technologies that offer earlier, more accurate detection and a better patient experience. The podcast draws on insights from recent industry data, regulatory updates, and the Company's own developments, offering a fresh perspective on Izotropic's mission and its flagship product, IzoView, a first-of-its-kind dedicated Breast CT Imaging System. This new communications platform repackages publicly disclosed information into a conversational format that's both educational and accessible to patients, healthcare professionals, and stakeholders across the breast health ecosystem. The Company intends to use the podcast to support broader awareness-building efforts as it advances IzoView toward regulatory approval and market launch. Episode 1 of the podcast is available now on the Company's YouTube channel. Subscribe to stay informed about future episodes covering breast imaging trends, patient advocacy, and medical imaging innovation. Podcast Sources Cited: Izotropic Corporation (July 29, 2025) Izotropic's IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies. [Press Release]. Izotropic Corporation (August 5, 2025) Izotropic's IzoView Positioned to Capitalize on Key Global Breast Imaging Market Drivers [Press Release]. Murphy, H. (2025, July 10). Over 100 AI-enabled radiology algorithms added to FDA's list of approvals. Health Imaging. Retrieved July 14, 2025, from Carey, L. (2025, July 14). Radiology drives July FDA AI-enabled medical device update. Retrieved July 14, 2025, from Allegretto, A. (2025, July 14). Rural women more prone to advanced-stage breast cancer. Retrieved July 14, 2025, from Murphy, H. (2025, July 16). Reimbursement for contrast-enhanced mammography is on the rise. Health Imaging. Retrieved July 16, 2025, from Murphy, H. (2025, July 15). GPT-4o's 'all or nothing' accuracy continues to hinder its radiologic capabilities. Health Imaging. Retrieved July 16, 2025, from About Izotropic: More information about Izotropic Corporation can be found on its website at and by reviewing its profile on SEDAR at Disclaimer & Forward-Looking Statements:This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for episodes are generated with the assistance of Google AI. Content was produced using generative tools and may contain machine-generated elements. Listeners are encouraged to verify all information through official sources. Contacts: Robert Thast, Interim Chief Executive Officer Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1 Email: bthast@ James Gagnon, International Communications Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2 General and Corporate Inquiries Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3 Email: info@ Corporate CommunicationsIBNAustin, OfficeEditor@ in to access your portfolio
